1. Limited Utility of Procalcitonin in Identifying Community-Associated Bacterial Infections in Patients Presenting with Coronavirus Disease 2019
- Author
-
Magdalena E. Sobieszczyk, Christine J. Kubin, Michael May, Jason Zucker, Michelle Chang, Justin C Laracy, Sherif Shoucri, Donald Dietz, and Anne-Catrin Uhlemann
- Subjects
Male ,2019-20 coronavirus outbreak ,Coronavirus disease 2019 (COVID-19) ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,Bacteremia ,Clinical Therapeutics ,030204 cardiovascular system & hematology ,Procalcitonin ,Community associated ,03 medical and health sciences ,0302 clinical medicine ,medicine ,Humans ,Pharmacology (medical) ,In patient ,030212 general & internal medicine ,Aged ,Pharmacology ,Coinfection ,business.industry ,COVID-19 ,Bacterial Infections ,Middle Aged ,bacterial infections and mycoses ,medicine.disease ,Virology ,Community-Acquired Infections ,antimicrobial stewardship ,Infectious Diseases ,Female ,business - Abstract
The role of procalcitonin in identifying community-associated bacterial infections among patients with coronavirus disease 2019 is not yet established. In 2,443 patients with 148 bacterial coinfections, mean procalcitonin levels were significantly higher with any bacterial infection (13.16 ± 51.19 ng/ml; P = 0.0091) and with bacteremia (34.25 ± 85.01 ng/ml; P = 0.0125) than without infection (2.00 ± 15.26 ng/ml)., The role of procalcitonin in identifying community-associated bacterial infections among patients with coronavirus disease 2019 is not yet established. In 2,443 patients of whom 148 had bacterial coinfections, mean procalcitonin levels were significantly higher with any bacterial infection (13.16 ± 51.19 ng/ml; P = 0.0091) and with bacteremia (34.25 ± 85.01 ng/ml; P = 0.0125) than without infection (2.00 ± 15.26 ng/ml). Procalcitonin (cutoff, 0.25 or 0.50 ng/ml) did not reliably identify bacterial coinfections but may be useful in excluding bacterial infection.
- Published
- 2021
- Full Text
- View/download PDF